Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets

Platelets

Volumn 14, Issue 1, 2003, Pages 15-20

  Jagroop, I Anita ^b   Burnstock, Geoffrey ^a   Mikhailidis, Dimitri P ^b,c  

^a Autonomic Neuroscience Institute   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 6 N (2 METHYLTHIOETHYL) 2 (3,3,3 TRIFLUOROPROPYLTHIO)ADENOSINE PHOSPHATE; ADENOSINE DIPHOSPHATE; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; PURINE P2X RECEPTOR; PURINE P2X RECEPTOR BLOCKING AGENT; PURINE P2Y RECEPTOR; PURINE P2Y RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; SEROTONIN; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; P2RY12 PROTEIN, HUMAN; PURINE P2 RECEPTOR; PURINE P2X1 RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR;

AGGREGOMETRY; APPARATUS; ARTICLE; CELL STRUCTURE; CHANNELYZER; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; MEASUREMENT; NORMAL HUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; TECHNIQUE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE SHAPE; THROMBOCYTE VOLUME; BLOOD CLOTTING PARAMETERS; CELL SIZE; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; INSTRUMENTATION; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTE COUNT;

ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; CELL SIZE; HUMANS; MEMBRANE PROTEINS; PLATELET ACTIVATION; PLATELET COUNT; PLATELET FUNCTION TESTS; RECEPTORS, PURINERGIC P2; SEROTONIN;

EID: 0037324241     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/0953710021000062914     Document Type: Article

References (42)

1. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Reviews 1998; 50: 413-491.
2. 12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001; 7: 443-447.
3. 12 in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002; 22: 686-691.
4. Gachet C. Identification, characterization, and inhibition of platelet ADP receptors. Int J Haematol 2001; 74: 375-381.
5. 12 receptor as a therapeutic target in cardiovascular disease. Platelets 2001; 12: 197-209.
6. Daniel J L, Dangelmaier C, Jin J, Ashby b, Smith J B, Kunapuli S P. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 2024-2029.
7. Whitworth N H, Barradas M A, Mikhailidis D P, Dandona P. An investigation into the effects of bacterial lipopolysaccharide on human platelets. Eur J Haematol 1989; 43: 112-119.
8. Mikhailidis D P, Barradas M A, O'Donoghue S, Dandona P. Evidence for in vivo platelet activation following the injection of conventional unfractionated heparin. Platelets 1990; 1: 189-192.
9. Barradas M A, O'Donoghue S, Mikhailidis D P. Measurement of platelet volume using a channelyzer: Assessment of the effect of agonists and antagonists. In vivo 1992; 6: 629-634.
10. Nystrom M L, Barradas M A, Mikhailidis D P. N-formyl-methionine-leucine-phenylalanine [fMLP], a bacterial chemotactic peptide, stimulates platelet shape change in human whole blood. Platelets 1993; 4: 156-158.
11. 2 synthesis: an in vitro study. Thromb Res 1993; 71: 227-236.
12. Nystrom M L, Barradas M A, Jeremy J Y, Mikhailidis D P. Platelet shape change in whole blood: differential effects of endotoxin. Thromb Haemost 1994; 71: 646-650.
13. Jagroop I A, Barradas M A, Mikhailidis D P. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin induced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol 1996; 41: 163-165.
14. Jagroop I A, Mikhailidis D P. Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Human Hypertens 2000; 14: 581-585.
15. Jagroop I A, Clathworthy I, Lewin J, Mikhailidis D P. Shape change in human platelet-measurements with a channelyzer and visualisation by electron microscopy. Platelets 2000; 11: 28-32.
16. Jagroop I A, Mikhailidis D P. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 2000; 11: 161-165.
17. Jagroop I A, Mikhailidis D P. Effect of endothelin-1 on human platelet shape change: reversal of activation by naftidrofuryl. Platelets 2000; 11: 272-277.
18. Jagroop I A, Mikhailidis D P. Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Human Hypertens 2001; 15: 203-207.
19. Maurer-Spurej E, Devine D V. Platelet aggregation is not initiated by platelet shape change. Lab Invest 2001; 81: 1517-1525.
20. Wilde J I, Retzer M, Siess S, Watson P. ADP-induced platelet shape change: an investigation of the signaling pathways involved and their dependence on the methods of platelet preparation. Platelets 2000; 11: 286-295.
21. Ehrman M L, Jaffe E A. Prostacyclin (PG12) inhibits the development in human platelets of ADP and arachidonic acid-induced shape change and procoagulant activity. Prostaglandins 1980; 20: 1103-1116.
22. Gabbasov Z A, Popov E G, Gavrilov I, Pozin E. Platelet aggregation: the use of optical density fluctuations to study microaggregate formation in platelet suspension. Thromb Res Suppl, 1989; 54: 215-223.
23. Kitek A, Breddin K. Optical density variations and microscopic observations in the evaluation of platelet shape change and microaggregate formation. Thromb Haemost 1980; 44: 154-158.
24. Elmer O, Goransson G, Saku M, Bengmark S. Ethanol-induced microaggregate formation in pig and rabbit blood. An in vitro study. Thromb Haemost 1977; 37: 344-350.
25. 1 receptors by N6-methyl 2′-deoxyadenosine 3′,5′-bisphophate. Br J Pharmacol 1998; 124: 1-3.
26. Humphries R G, Tomlinson W, Ingall A H, Cage P A, Leff P. FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br J Pharmacol 1994; 113: 1057-1063.
27. 2/3 receptors. Mol Pharmacol 1998; 53: 969-973.
28. 1 receptor antagonist. Eur J Pharmacol 2001; 412: 213-221.
29. 1 purinergic receptor: synthesis and conformational analysis using potentiometric and nuclear magnetic resonance titration techniques. J Med Chem 2002; 45: 962-972.
30. 1 purinoceptors with α,β-methylene ATP. Thromb Haemost 2001; 85: 303-308.
31. 1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 1997; 78: 1500-1504.
32. 1 purinoceptors for platelet aggregation. Eur J Pharmacol 1999; 372: 305-309.
33. 1 receptor function in murine megakaryocytes and human platelets reveals synergy with P2Y receptors. Br J Pharmacol 2002; 135: 363-372.
34. Horner S, Ganso M, Braun K, Hildebrandt C, Lambrecht G. Is MRS2179 P2Y1-selective in whole tissues? Proceedings of 7th international symposium on adenosine and adenine nucleotides. Gold Coast Australia. 2002; page105: abstract 236.
35. Puri R N, Colman R W. ADP-induced platelet activation. Crit Rev Biochem Mol Biol 1997; 32:437-502.
36. CAPRIE steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
37. Yusuf S, Zhao F, Metha S R, Chrolavicius S, Tognoni G, Fox K K. The clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
38. Mikhailidis D P, Jagroop I A. Is clopidogrel markedly superior to aspirin in patients with peripheral vascular disease? Platelets 1998; 9: 273-278.
39. 2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999; 42: 213-220.
40. Robless P, Mikhailidis D P, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88: 787-800.
41. Savi P, Pereillo J M, Uzabiaga M F, Combalbert J, Picard C, Maffrand J P, Pascal M, Herbert J M. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-896.
42. 12, play a role in the platelet shape change phenomenon in humans. Platelets 2002; 13: 340-341.